https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-023-05917-8

Impact of the COVID-19 pandemic on delays in diagnosis and treatment of tick-borne diseases endemic to southeastern USA

Victor Arahirwa, Katherine Tyrlik, Haley Abernathy, Caitlin Cassidy, Aidin Alejo, Odai Mansour, Dana Giandomenico, Amanda Brown Marusiak & Ross M. Boyce

Abstract

Background

The Coronavirus disease 2019 (COVID-19) pandemic was marked by an increase in diagnosis and treatment delays for a range of medical conditions. Yet the impact of the pandemic on the management of tick-borne diseases, which frequently manifest as an acute febrile illness similar to COVID-19, has not been well described.

Methods

In this retrospective cohort study of patients with suspected tick-borne disease attending the University of North Carolina Health facilities, we compared the timeliness of diagnosis and treatment in a “pre-COVID” period (March 2019 to February 2020) and a “post-COVID” period (March 2020 to February 2021). Participants included patients with an ICD-10 diagnosis code of spotted fever group rickettsiosis or ehrlichiosis and a positive Rickettsia rickettsii or Ehrlichia indirect immunofluorescence assay immunoglobulin G antibody test result. Of the 897 patients who had an eligible diagnosis, 240 (26.8%) met the inclusion criteria. The main outcome was time from initial presentation to definitive diagnosis and treatment.

Results

During the 2-year study period, 126 (52.5%) patients were grouped in the pre-COVID period and 114 (47.5%) were grouped in the post-COVID period; 120 (50.0%) were female; and 139 (57.9%) were aged > 50 years. Comparing the post-COVID to the pre-COVID period, the adjusted odds ratio (aOR) for delay in treatment > 0 days was 1.81 (95% confidence interval [CI] 1.07–3.07, P = 0.03), and for a treatment delay > 7 days, 1.65 (95% CI 0.94–2.90, P = 0.08). The odds of a delay in diagnosis were similar for patients in the post- and pre-COVID periods, with an aOR of 1.61 (95% CI 0.96–2.72, P = 0.07) for delays > 0 days, and aOR of 1.72 (95% CI 0.99–3.00, P = 0.05) for delays > 7 days.

Conclusions

The odds of a delay in treatment > 0 days were significantly higher in the post-COVID period than in the pre-COVID period. However, the odds of a delay in treatment > 7 days, or a delay in diagnosis, were similar between these two periods. Shifts in care-seeking, alternative care delivery models and prioritization of COVID-19 may contribute to diminished timeliness of treatment for patients with tick-borne diseases.

For more:

https://www.lymedisease.org/will-lyme-lawsuit-against-idsa-be-revived/

Will Lyme lawsuit against IDSA be revived?

Sept. 11, 2023

Two years ago, a federal court dismissed Torrey v. IDSA, a lawsuit brought by a group of Lyme patients against the Infectious Diseases Society of America.

The patients have appealed the court’s dismissal, and last week, an appeal hearing was held. We don’t know when the court will make its ruling as to whether the lawsuit can go forward.

By Cameron Langford, Courthouse News Service

A group of Lyme disease patients asked the Fifth Circuit on Thursday to revive their lawsuit against a medical society they claim issued bogus guidelines that insurers used to deny them coverage, forcing some to pay hundreds of thousands of dollars for their care.

Each year, around 30,000 people in the U.S. are diagnosed with Lyme disease, according to the Centers for Disease Control and Prevention.

But because not all cases are reported and not everyone knows they have been infected, the CDC estimates 476,000 people may get the disease in the U.S. each year.

It is transmitted from the bites of ticks, who pick up the bacteria from feeding on the blood of infected birds, mice and deer. People often get a large red bullseye-like rash around the bites.

If untreated, it can cause nervous system damage, neurological and heart issues, and joint pain. Some patients who receive antibiotics still develop serious health problems.

The threat is growing: Counties classified as high risk for the disease increased more than 300% from the mid-1990s to 2015, according to a report in the Journal of Medical Entomology.

Epidemiologists attribute that to climate change and urbanization: Places that once had winter temperatures that killed the blacklegged vector ticks are now warm enough throughout the year for them to thrive, and growing suburbs put residents closer to the habitats of animals from whom ticks contract the bacteria.

Suing the IDSA

Lisa Torrey and 27 others sued the Infectious Diseases Society of America, or IDSA, seven health insurance companies and several medical doctors in 2017 in Texarkana, Texas, federal court.

Suffering from hearing problems, migraine headaches, and an irregular heartbeat, Torrey said she visited 36 doctors, some of whom misdiagnosed her with multiple sclerosis and fibromyalgia and said her symptoms “were all in her head,” before she was correctly diagnosed with Lyme disease.

She blamed her difficulties on the IDSA, a group of more than 12,000 physicians, scientists and public health experts who treat and develop guidelines about appropriate care for infectious diseases.

Bringing RICO Act and antitrust claims, the plaintiffs claim several major health insurers decided treating Lyme disease was too expensive, so they paid IDSA-affiliated doctors to establish arbitrary guidelines, first published in 2000, that said the illness could be treated with 28 days of antibiotics.

The plaintiffs also claim they had trouble finding doctors who would treat them because the IDSA and insurers referred physicians who criticized the guidelines as too restrictive to state medical boards, and more than 50 were investigated, disciplined or had their licenses removed.

Controversy

Long-term Lyme disease has been a subject of controversy for years.

The IDSA’s 2000 guidelines said there was insufficient evidence to regard chronic Lyme disease as a separate diagnosis.

Its 2006 guidelines stated, “In many patients, post-treatment symptoms appear to be more related to the aches and pains of daily living rather than to either Lyme disease or another tick-borne infection.”

Torrey says that due to the association’s guidance she has been forced to pay hundreds of thousands of dollars to treat her Lyme disease because her insurers have denied her coverage.

After reaching confidential settlements with the insurers, the plaintiffs filed a second amended complaint in January 2021, adding fraudulent and negligent misrepresentation claims against the IDSA and its panelists who wrote the guidelines.

The plaintiffs further whittled their case in April 2021, after lodging a third amended complaint, by dismissing the panelists as defendants and their RICO claims.

U.S. District Judge Robert Schroeder, a Barack Obama appointee, sided with the IDSA in September 2021, first dismissing the challengers’ antitrust claims, and their misrepresentation allegations in a separate order two weeks later.

Appeal

Torrey and company appealed to the Fifth Circuit the next month. But the IDSA convinced the New Orleans-based appellate court to dismiss the appeal as premature because plaintiffs’ settlements with the health insurers had not been finalized.

The plaintiffs filed another appeal last November and a three-judge panel of the Fifth Circuit heard arguments Thursday.

Representing the Lyme patients, Kendall Speer of the Houston firm Rusty Hardin & Associates said Schroeder had erred by concluding plaintiffs could not win on their misrepresentation claims because the statements in IDSA’s guidelines were medical opinions and not held out as facts.

Schroeder also said the plaintiffs’ doctors can review the studies and papers cited in the IDSA guidelines and make their own assessments about their accuracy.

But Speer argued her clients’ doctors are not capable of exercising their own independent judgment on the proper way to treat chronic Lyme disease due to the “substantial power and influence” the IDSA has in dictating how physicians can care for such patients.

Leaning towards dismissal?

U.S. Circuit Judge Kyle Duncan indicated he is leaning towards affirming dismissal of the lawsuit.

“My concern here is there has to be a forum for debating scientific questions,” the Donald Trump appointee told Speer. “And this is a scientific question — how to treat this. We all know that. There has to be a forum for that. And we can’t have lawsuits against people who are debating the scientific question in a forum.”

The IDSA’s counsel, Alvin Dunn, played up Duncan’s concerns.

He said the plaintiffs themselves have acknowledged in their filings the IDSA’s guidelines are part of an ongoing scientific and medical debate, which by its nature is subject to change.

“New evidence can always come along, new drugs can come along, new treatments can come along, if you allow these misrepresentation claims it’s very dangerous to quash that debate,” argued Dunn, who is with the Washington firm Pillsbury Winthrop Shaw.

Speer, the challengers’ lawyer, countered it is plausible doctors are effectively bound by the guidelines, evidenced by the fact more than 12 states have passed legislation to protect physicians’ ability to prescribe long-term Lyme treatment.

U.S. Circuit Judge Edith Jones, a Ronald Reagan appointee, asked Speer if the legislation was meant to force insurers to cover this treatment.

“Yes, I think it’s tied together,” Speer replied. “I think it’s because of the harm the public is suffering because of the ability to get the care, so I think those states have recognized that.”

U.S. Circuit Judge Carl Stewart, a Bill Clinton appointee, filled out the panel.

The judges gave no word on when they would issue a ruling.

________________

For more:

https://popularrationalism.substack.com/p/its-time-you-read-the-truth-about

It’s Time You Read the Truth About Dr. Andrew Wakefield

R-Calrizian’s Medium article written by Mary Holland deserves your time. Daily Mail’s Censorship of Dr. Ahmad Malik means you should share this on Social Media. Please Restack and Post everywhere.

JUL 24, 2023

Let the Daily Mail see the effect of their censorship. Share this post.

A Thorough Analysis of the Case Against Dr. Andrew Wakefield by Mary Holland, JD

Mary Holland (was) is a research scholar at NYU School of Law. She has written and edited books and articles on human rights and law. She has clerked for a federal judge, worked at the Lawyers Committee for Human Rights and at prominent U.S. law firms. She graduated from Harvard College and holds graduate degrees from Columbia University. She is a co-founder and board member of the Center for Personal Rights.

Introduction

If you’ve heard Dr. Wakefield’s name — and you probably have — you’ve heard two tales. You’ve heard that Dr. Wakefield is a charlatan, an unethical researcher, and a huckster who was “erased” from the British medical registry and whose 1998 article on autism and gastrointestinal disease was “retracted” by a leading medical journal. You’ve also heard a very different story, that Dr. Wakefield is a brilliant and courageous scientist, a compassionate physician beloved by his patients, and a champion for families with autism and vaccine injury. What’s the truth?

Who is Dr. Andrew Wakefield?

Dr. Wakefield graduated from St. Mary’s Hospital Medical School of the University of London in 1981; he was one in the fourth generation of his family to study medicine at that teaching hospital. He pursued a career in gastrointestinal surgery with a specialty in inflammatory bowel disease. He became a Fellow of the Royal College of Surgeons in 1985 and was accepted into the Royal College of Pathologists in 2001. He held academic positions at the Royal Free Hospital and has published over 140 original scientific articles, book chapters, and invited scientific commentaries.

Background on The Controversy

In the early 1990s, Dr. Wakefield began to study a possible link between the measles virus and bowel disease. He published a 1993 study, “Evidence of persistent measles virus infection in Crohn’s disease” and co-authored a 1995 article published in The Lancet, “Is measles vaccine a risk factor for inflammatory bowel disease?” At roughly the same time, Dr. Wakefield wrote an unpublished 250-page manuscript reviewing the available scientific literature on the safety of measles vaccines. He was rapidly emerging as one of the world’s experts on measles vaccination.

In 1996, an attorney, Solicitor Barr of the law firm Dawbarns, contacted Dr. Wakefield to ask if he would serve as an expert in a legal case on behalf of children injured by vaccines containing the measles virus. The lawyer was bringing the suit on behalf of parents who alleged that vaccines had caused their children’s disabilities, including autism. Six months before this, and independent of the litigation effort, parents of children with autism and severe gastrointestinal symptoms began contacting Dr. Wakefield because of his publications on the measles vaccine, asking for help for their children’s pain and suffering, which they believed was vaccine-induced. Dr. Wakefield made two major, but separate, decisions at about this time — to try to help the families dealing with autism and gastrointestinal problems, and to become an expert in the legal case regarding vaccines and autism.

Barr asked Dr. Wakefield to study two questions:

(1) whether measles could persist after measles infection or the receipt of the MMR vaccine; and

(2) whether the measles virus could lead to complications, such as Crohn’s disease or autism.

Due to bureaucratic delays at his hospital, however, Dr. Wakefield did not begin this litigation-related study until October 1997. By July 1997, Dr. Wakefield and his colleague, Professor John Walker-Smith, had already examined the “Lancet 12” — twelve patients with autism and gastrointestinal symptoms that were the basis for the case study in the 1998 article published in The Lancet. Dr. Wakefield and others had recommended the referral of these patients to Prof. Walker-Smith, an eminent physician described by his peers as one of the world’s leading pediatric gastroenterologists.

Prof. WalkerSmith had recently moved to St. Mary’s Hospital from a different institution and brought with him the same clinical privileges and ethical clearances that he enjoyed at his previous hospital. He, a colleague, Dr. Simon Murch, and a team of other physicians, did extensive clinical workups on these sick children that Prof. Walker-Smith deemed “clinically indicated,” while Dr. Wakefield coordinated a detailed research review of the tissues obtained at biopsy. The clinical tests included colonoscopies, MRI scans, and lumbar punctures to assess mitochondrial disorders. “Clinically indicated studies” did not require permissions from The Royal Free Hospital ethics committee because the tests were required for the benefit of the individual patients. Dr. Wakefield’s research was covered by an appropriate ethical approval.

In 1998, to announce the publication of The Lancet article coauthored by Dr. Wakefield and twelve other scientists, the dean of St. Mary’s Medical School called a press conference. While this was not standard practice, the dean presumably was seeking to enhance the school’s visibility in cutting-edge research. The article was labeled in the medical journal as an “early report,” stating that it “did not prove an association between measles, mumps and rubella vaccine and the syndrome described. Virological studies are underway that may help to resolve this issue.”

At the press conference, Dr. Wakefield was asked about the safety of the MMR vaccine. In 1992, two different combination MMR vaccines had been withdrawn from the U.K. marketplace because they were unsafe, so MMR vaccination was already a hot topic before The Lancet article was published. Dr. Wakefield responded that, given the paucity of combination MMR vaccine safety research, and until further safety studies were done, the vaccines should be separated into their component parts. He had previously informed his colleagues that this was his view and that he would express it if asked.

The 1998 press conference set off a media firestorm, with large numbers of parents raising uncomfortable questions about the safety of the “triple jab” and requesting single measles, mumps, and rubella vaccines. In the midst of the controversy, in August 1998, the British government took an extraordinary step. It made separate measles, mumps, and rubella vaccine components unavailable, thereby forcing the hand of concerned parents. At that point, measles vaccination rates among children in the United Kingdom fell significantly. Measles disease outbreaks became more prevalent and included a handful of cases of serious complications and deaths. Some sought to blame Dr. Wakefield for irresponsibly scaring parents and triggering a public health crisis. The British government had a big problem on its hands — one that would soon make its way to the United States.

The controversy surrounding Dr. Wakefield simmered. In February 2004, it reached a boiling point when Dr. Richard Horton, editor of The Lancet, held a news conference to declare that the 1998 article was “fatally flawed” because Dr. Wakefield had failed to disclose financial conflicts of interest with the litigation-related study he conducted. British reporter Brian Deer published the story in the Sunday Times, detailing alleged undisclosed conflicts of interest. Immediately following publication, Mr. Deer sent a detailed letter to the British General Medical Council (GMC), which regulates the practice of medicine. The GMC then initiated proceedings against Dr. Wakefield that culminated in Dr. Wakefield’s delicensure in May 2010 and the retraction of the 1998 article from The Lancet.

The Allegations against Dr. Wakefield

The highly publicized, multi-year, multi-million dollar prosecution against Dr. Wakefield alleged that:

•Dr. Wakefield was paid 55,000 British pound sterling (about US $90,000) by litigators for the study published in The Lancet, and he failed to disclose this conflict of interest;

•He and his colleagues performed medically unnecessary tests on the children in the 1998 study and lacked appropriate ethical clearances;

•The children in the 1998 study were selected for litigation purposes (as described in the Sunday Times article) and not referred by local physicians; and

•He drew blood from children at his son’s birthday party for control samples in the 1998 study with callous disregard for the distress that this might cause children.

Based on its findings, the GMC concluded that Dr. Wakefield had engaged in “serious professional misconduct,” and “dishonest,” “misleading,” and “irresponsible” behavior, warranting the sanction of his removal from the medical profession.

Let’s examine the GMC’s charges and the evidence.

Failure to Disclose Payment from Litigators

Dr. Wakefield accepted 55,000 pounds to conduct a study for the class action suit regarding vaccines and autism. This was a research grant from which Dr. Wakefield personally received no compensation. Dr. Wakefield did not start this study until after the case series for the Lancet 12 had been submitted. Legal documents prove that Dr. Wakefield’s hospital knew about this study and knew about the amount of money he received, most of which went to pay the salary of a designated laboratory technician. Documents further demonstrate that Dr. Wakefield disclosed in a national newspaper over one year before publication of the 1998 article that he was working with the litigators. Dr. Horton, editor of The Lancet, had been informed and should have been well aware of Dr. Wakefield’s role in the vaccine-related litigation before the publication of the 1998 article.

“Medical Necessity” and Ethical Clearances

The Lancet 12 were sick. Each child was administered tests with the intent to aid that child. The hospital administration was fully aware of the tests being conducted and made no objections. Because all of the tests were “clinically indicated” and not for research purposes, no ethical clearance beyond what Prof. Walker-Smith already possessed was required. Notably, no patient, parent, or guardian has ever made accusations against Dr. Wakefield or testified against him for ethical violations or medically unnecessary procedures. Dr. Wakefield and his colleagues reject the GMC’s ruling that the tests for the Lancet 12 were unnecessary.

The Lancet 12’s Referrals

The GMC charged that the children were referred through the litigation effort and not through ordinary medical channels. This is incorrect. Parents started contacting Dr. Wakefield long before the litigation started, and independently of it. Since the litigation study was not yet started by the time The Lancet study was completed and submitted to the journal, this finding is false. Dr. Wakefield and his colleagues reject that claim; the families contacted them directly because of their medical expertise.

Control blood samples from a child’s birthday party

Dr. Wakefield arranged for control blood samples from healthy, typically developing children to be taken at his son’s birthday party. Most of the children’s parents were medical colleagues and friends. He did this with the children’s and parents’ fully informed consent and gave the children 5 pounds each for their trouble. The procedure was undertaken by an appropriately qualified doctor using a standard technique. The children were happy to be helpful and went on to enjoy the birthday party. While this is admittedly an unconventional method of collecting control blood samples, it hardly amounts to “serious professional misconduct” or an ethical breach warranting delicensure. The GMC’s description of this incident as an example of “callous disregard” for children’s distress seems to be a gross exaggeration. Indeed, the U.K. High Court of Justice exonerated Professor Walker-Smith in March 2012, and the Lancet journal has suggested that it is considering reversing its retraction.

The GMC failed to prove its case against Dr. Wakefield. Using Brian Deer’s reporting as evidence, the GMC appears to have purposefully conflated the Lancet 12 study and the subsequent litigation study to create the appearance of a financial conflict of interest. Similarly, the GMC appears to have wrongfully applied ethical research standards to tests that were “clinically indicated” for severely ill children. Conflating treatment and research not only grievously harmed Dr. Wakefield and his colleagues but set a threatening precedent for the practice of medicine. The government’s medical regulators (of uncertain expertise) second-guessed Prof. Walker-Smith, the world’s preeminent authority on pediatric gastroenterology, on his clinical judgment about what tests were necessary.

Which medical decisions will regulators second-guess next? The press, and specifically reporter Brian Deer, tried Dr. Wakefield in the court of public opinion while the GMC was prosecuting him in its regulatory court. Deer alleged that Dr. Wakefield had a pending patent application for a separate measles vaccine and hoped to “cash in” by urging parents to forego the MMR for separate measles vaccines. The evidence proves that Dr. Wakefield was not a patent holder for a separate measles vaccine. St. Mary’s Hospital held a patent for a therapeutic single measles vaccine using the beneficial immune properties of transfer factor, intended for people already infected with the measles virus. This measles vaccine was not a preventive product for people unexposed to the virus; in other words, there was no possible financial competition between the MMR vaccine and the single measles vaccine for which the hospital, and not Dr. Wakefield, held a patent.

In 2009, Deer made additional allegations that Dr. Wakefield fabricated data. The GMC never made this charge, but the media picked it up and, notably, the U.S. Department of Justice used it frequently in the Omnibus Autism Proceeding in the U.S. Court of Federal Claims. In those proceedings to determine whether families could receive compensation for MMR-induced autism, the US Department of Justice went out of its way to depict Dr. Wakefield as a scientific fraud, although he was not directly relevant to the proceedings. In his 2010 book, Callous Disregard, Dr. Wakefield shows Deer’s allegations of fraud to be fabrications.

CPR finds no evidence of Dr. Wakefield’s scientific fraud. On the contrary, many scientists and laboratories around the world have confirmed Dr. Wakefield’s findings regarding severe gastrointestinal inflammation and symptoms in a high percentage of children with autism. In its February 2, 2010 retraction, The Lancet did not allege fraud. Relying solely on the GMC proceeding, it retracted the article, asserting that the authors had not referred the patients as represented and the study team had not received the hospital’s ethics committee’s approval. The GMC’s conclusions and The Lancet’s reliance on them appear unfounded.

The Meaning of The Wakefield Prosecution

What, then, was this high-profile prosecution really about? If there was no scientific fraud, no undisclosed financial conflicts of interest, no ethical breaches in performing tests on sick children, and no complaints from patients or their families, then what was the big deal? Did the international scandal and multi-million dollar prosecution proceed merely to chastise a doctor for drawing blood from children at a birthday party, with their consent and their parents’ consent? Of course not.

Dr. Wakefield was, and remains, a dissident from medical orthodoxy. The medical establishment subjected him to a modern-day medical show trial for his dissent. Dr. Wakefield’s research raised fundamental doubts about the safety of vaccines and the etiology of autism. Dr. Wakefield was punished for his temerity to caution the public about vaccine risks and to urge them to use their own judgment. Dr. Wakefield was punished for upholding vaccination choice.

The purpose of the proceeding, as in any show trial, was to communicate to other doctors and scientists, and to the public, the error of the perpetrator’s ways. A show trial offers a veneer of due process but, at its core, displays naked power. The apparent intent of the prosecution was to intimidate others from following Dr. Wakefield’s footsteps and to teach the lesson that anyone in the medical or scientific community who dares to publicly question the safety and efficacy of vaccines will be punished with utmost severity. The GMC appears to have decided that if the price of such a lesson was scientific ignorance about vaccine-autism links and the suffering of severely ill children, then so be it. Dr. Wakefield was made an example.

The GMC destroyed Dr. Wakefield’s professional reputation and livelihood, and The Lancet and other publications confiscated his professional accomplishment through retraction. The GMC colluded with The Lancet, the media, the British Department of Health, the pharmaceutical industry, and even with the U.S. Department of Health and Human Services and the U.S. Department of Justice, to discredit Dr. Wakefield. The Center for Personal Rights is confident that the world will look back at the prosecution of Dr. Wakefield, Walker-Smith, and Murch with shame and remorse.

In due course, the world has paid tribute to human rights dissidents, as well — Nelson Mandela moved from prison in South Africa under apartheid to become its most beloved President; Andrei Sakharov left Russia’s internal exile to become its moral beacon; Vaclav Havel left a Czech prison to become its first post-communist President; and Liu Xiabo, a Chinese human rights advocate, received the 2010 Nobel Peace Prize in absentia because he remains incarcerated. In time, China will embrace Mr. Liu and look to him to help create a better future. Before long, the world will likely recognize that it was Dr. Wakefield, not his detractors, who stood up for the practice of medicine and the pursuit of science. Dr. Wakefield remains an unbowed dissident in the face of a repressive medical and scientific establishment.

Dr. Andrew Wakefield

Original Source: A Thorough Analysis of the Case Against Dr. Andrew Wakefield by Mary Holland, JD

________________

For more:

https://principia-scientific.com/the-climate-emergency-is-coming-for-you/

The ‘Climate Emergency’ Is Coming For You

Written by Andy Kessler

Two years ago during Covid lockdowns, I wrote about climate control freaks, facetiously anticipating a future headline: “Bad CO2 Day, Lockdowns Enforced.” A joke that would never happen, right? Well . . .

Last month President Biden was asked on the Weather Channel if he was ready to declare a national climate emergency and responded, “We’ve already done that.”

Asked again if he declared a climate emergency, he said, “Practically speaking, yes.” There is no official emergency, but the president certainly thinks we need one.

The fawning press gave him a break—he didn’t really mean that, did he? But the notion of a national emergency today isn’t farfetched.

The United Nations website blares: “What you need to know about the Climate Emergency.” The European Parliament has declared one. So have hundreds of jurisdictions in at least 39 countries, including the U.K., Canada, Japan, and Bangladesh.

Climate-activist teenager Greta Thunberg gave away the game in 2019 when she said, “I want you to panic,” and, “I want you to act as if you would in a crisis.” Emergencies are an excuse to do whatever you want.

U.S. presidents can declare national emergencies, as spelled out in the 1976 National Emergencies Act, but they must be explicit:

“When the President declares a national emergency, no powers or authorities made available by statute for use in the event of an emergency shall be exercised unless and until the President specifies the provisions of law under which he proposes that he or other officers will act.”

I’ve searched far and wide for such provisions and can’t find them.

No matter, we’re living as if we’re already under emergency conditions. As of Aug. 1, the Biden administration has halted the sale of lightbulbs with less than 45 lumens of brightness per watt.

Incandescent bulbs don’t make the cut and are now banned. Thomas Alva Edison is rolling over in his grave.

Will electricity be rationed next?

Oops, too late.

In September 2022, the California Independent System Operator—which runs the state’s power grid, attached to sporadic renewables—declared an “energy emergency alert,” urging residents to ration power from 4 to 9 p.m.

In March, the European Union mandated energy consumption be cut by 11.7 percent by 2030. Brits are urged to turn their heat off at night for “emissions savings.”

The Swiss considered jail time if your thermostat is set above 66 degrees in the winter.

Sit in the cold and dark and like it! And wait till you see the menu. The EU already allows crickets and mealworm larvae as food. Are high-protein maggots next?

This nonsense could never happen in the U.S., could it? Well, in 2016, New York University professor Matthew Liao suggested, “Possibly we can use human engineering to make the case that we’re intolerant to certain kinds of meat.”

He even suggested deploying a “Lone Star tick where, if it bites you, you will become allergic to meat.”

Add to the mix the C40 Cities Climate Leadership Group, which has an “ambitious target in 2030” of no meat, no dairy, no private vehicles, and only “three new clothing items per person per year.” Plus one short flight every three years.

That sounds like a climate lockdown to me.

Who are these kooks? “A global network of nearly 100 mayors” including 14 in America: Austin, Texas; Boston; Chicago; Houston; Los Angeles; Miami; New Orleans; New York; Philadelphia; Phoenix; Portland, Ore.; San Francisco; Washington and Seattle. Michael Bloomberg is the president of the board. Better stock up on socks while you can.

When you declare an emergency, anything goes. The Biden administration pushes electronic vehicles, and this summer we had a glut of them—inventories were 92 days, double what is typical.

As of midyear, Ford had 116 days of unsold Mustang Mach-Es.

Maybe because saner Americans are becoming preppers and loading up on good old gasoline-fired cars before California’s Advanced Clean Cars II Regulations, which other states follow, outlaws them in 2035. Vroom, vroom.

Emergency-preparedness edicts abound: Gas stove bans. No plastic bottles for sale at San Francisco Airport. A new proposal from New York City’s Department of Environmental Protection would effectively ban coal- and wood-fired pizza ovens.

A city official reports that fewer than 100 restaurants would have to install prohibitively expensive emissions controls, so it must be a real emergency if New York is tracking down these last few ounces of ‘carbon’.

Climate lockdowns still sound like crazy-town, but the urge to curtail individual freedom is visible in countless government, media, and think-tank blueprints for a controlled future.

Saner minds should prevail—the Climate Emergency Act of 2021 evidently died in committee—but we need constant diligence to stand guard against the climate-excuse assaults on our liberties.

To show how adolescent this has become, last year Swiss Environmental Minister Simonetta Sommaruga suggested that residents “shower together” to save energy. OK, now we’re getting somewhere.

See more here climatechangedispatch

Header image: Janata Weekly

_________________

**Comment**

Those desiring climate lockdowns also want dietary and energy controls, ‘carbon’ restrictions and ‘climate change’ linked together whether it makes sense or not.  The UN and WEF’s The Great Reset plan includes ‘smart’ (15 minute) cities, limits on travel, new food systems (insects replacing meat and a new spate of genetically engineered frankinfood), a full switch to ‘green’ energy (wind and solar) and more, and all of these changes will go more smoothly if there is a central power, such as WHO.

https://www.mdpi.com/2076-0817/12/7/962

Lactate Dehydrogenase Inhibitors Suppress Borrelia burgdorferi Growth In Vitro

1Department of Microbiology, University of Massachusetts, Amherst, MA 01003, USA
2Department of Biochemistry, University of Massachusetts, Amherst, MA 01003, USA
3Invasive Insect Biocontrol & Behavior Laboratory, USDA-ARS, Beltsville, MD 20705, USA
*
Author to whom correspondence should be addressed.
Pathogens 2023, 12(7), 962; https://doi.org/10.3390/pathogens12070962
Received: 25 June 2023 / Revised: 15 July 2023 / Accepted: 19 July 2023 / Published: 22 July 2023
(This article belongs to the Section Ticks)

Abstract

Borrelia burgdorferi, the causative agent of Lyme disease, has a highly reduced genome and relies heavily on glycolysis for carbon metabolism. As such, established inhibitors of lactate dehydrogenase (LDH) were evaluated in cultures to determine the extent of their impacts on B. burgdorferi growth. Both racemic and enantiopure (AT-101) gossypol, as well as oxamate, galloflavin, and stiripentol, caused the dose-dependent suppression of B. burgdorferi growth in vitro. Racemic gossypol and AT-101 were shown to fully inhibit spirochetal growth at concentrations of 70.5 and 187.5 μM, respectively. Differences between racemic gossypol and AT-101 efficacy may indicate that the dextrorotatory enantiomer of gossypol is a more effective inhibitor of B. burgdorferi growth than the levorotatory enantiomer. As a whole, LDH inhibition appears to be a promising mechanism for suppressing Borrelia growth, particularly with bulky LDH inhibitors like gossypol.  (See link for article)
_______________
**Comment**
Lactate dehydrogenase inhibitors (LDH) are used in various assays for cancer and other research areas. They are also a promising target for cancer therapy.
For more: